collection
MENU ▼
Read by QxMD icon Read
search

Lymphoma

shared collection
43 papers 25 to 100 followers My list of recent lymphoma publications
https://www.readbyqxmd.com/read/27904766/the-role-of-pim1-in-the-ibrutinib-resistant-abc-subtype-of-diffuse-large-b-cell-lymphoma
#1
Hsu-Ping Kuo, Scott A Ezell, Sidney Hsieh, Karl J Schweighofer, Leo Wk Cheung, Shiquan Wu, Mutiah Apatira, Mint Sirisawad, Karl Eckert, Yu Liang, Jeff Hsu, Chun-Te Chen, Darrin Beaupre, Betty Y Chang
Diffuse large B cell lymphoma (DLBCL) is a heterogeneous lymphoma and the most common subtype of non-Hodgkin lymphoma, accounting for roughly 30% of newly diagnosed cases in the United States. DLBCL can be separated into the activated B cell-like (ABC) and germinal center B cell-like (GCB) subtypes, with distinct gene expression profiles, oncogenic aberrations, and clinical outcomes. ABC-DLBCL is characterized by chronically active B-cell receptor (BCR) signaling that can be modulated by Bruton's tyrosine kinase (BTK) activity...
2016: American Journal of Cancer Research
https://www.readbyqxmd.com/read/27650702/cutaneous-b-cell-lymphomas-2016-update-on-diagnosis-risk-stratification-and-management
#2
Ryan A Wilcox
DISEASE OVERVIEW: Approximately one-fourth of cutaneous lymphomas are B-cell derived and are generally classified into three distinct subgroups: primary cutaneous follicle center lymphoma (PCFCL), primary cutaneous marginal zone lymphoma (PCMZL), and primary cutaneous diffuse large B-cell lymphoma, leg type (PCDLBCL, LT). DIAGNOSIS: Diagnosis and disease classification is based on histologic review and immunohistochemical staining of an appropriate skin biopsy. Pathologic review and an appropriate staging evaluation are necessary to distinguish primary cutaneous B-cell lymphomas from systemic B-cell lymphomas with secondary skin involvement...
October 2016: American Journal of Hematology
https://www.readbyqxmd.com/read/27708232/a-strong-host-response-and-lack-of-myc-expression-are-characteristic-for-diffuse-large-b-cell-lymphoma-transformed-from-nodular-lymphocyte-predominant-hodgkin-lymphoma
#3
Bianca Schuhmacher, Benjamin Rengstl, Claudia Döring, Julia Bein, Sebastian Newrzela, Uta Brunnberg, Hans Michael Kvasnicka, Martine Vornanen, Ralf Küppers, Martin-Leo Hansmann, Sylvia Hartmann
Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) is an indolent lymphoma, but can transform into diffuse large B cell lymphoma (DLBCL), showing a more aggressive clinical behavior. Little is known about these cases on the molecular level. Therefore, the aim of the present study was to characterize DLBCL transformed from NLPHL (LP-DLBCL) by gene expression profiling (GEP). GEP revealed an inflammatory signature pinpointing to a specific host response. In a coculture model resembling this host response, DEV tumor cells showed an impaired growth behavior...
September 30, 2016: Oncotarget
https://www.readbyqxmd.com/read/27805626/pd-1-pd-l1-immune-checkpoint-blockade-in-b-cell-lymphomas
#4
REVIEW
Aaron Goodman, Sandip P Patel, Razelle Kurzrock
Cancer cells can escape T-cell-mediated cellular cytotoxicity by exploiting the inhibitory programmed cell-death protein 1 (PD-1)/programmed cell death 1 ligand 1 (PD-L1) immune checkpoint. Indeed, therapeutic antibodies that block the PD-1-PD-L1 axis induce durable clinical responses against a growing list of solid tumours. B-cell lymphomas also leverage this checkpoint to escape immune recognition, although the outcomes of PD-1-PD-L1 blockade, and the correlations between PD-L1 expression and treatment responses, are less-well elucidated in these diseases than in solid cancers...
November 2, 2016: Nature Reviews. Clinical Oncology
https://www.readbyqxmd.com/read/27701070/esmo-consensus-conference-on-malignant-lymphoma-general-perspectives-and-recommendations-for-prognostic-tools-in-mature-b-cell-lymphomas-and-chronic-lymphocytic-leukaemia
#5
M Ladetto, C Buske, M Hutchings, M Dreyling, G Gaidano, S Le Gouill, S Luminari, C Pott, A Zamò, E Zucca
The European Society for Medical Oncology (ESMO) consensus conference on mature B-cell lymphomas and chronic lymphocytic leukaemia (CLL) was held on 20 June 2015 in Lugano, Switzerland, and included a multidisciplinary panel of 25 leading experts. The aim of the conference was to develop recommendations on critical subjects difficult to consider in detail in the ESMO Clinical Practice Guidelines. The following areas were identified: (i) the elderly patient, (ii) prognostic factors suitable for clinical use and (iii) the 'ultra-high-risk' group...
October 4, 2016: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/27351173/management-strategies-and-outcomes-for-very-elderly-patients-with-diffuse-large-b-cell-lymphoma
#6
Dai Chihara, Jason R Westin, Yasuhiro Oki, Mohamed A Ahmed, Bryan Do, Luis E Fayad, Fredrick B Hagemeister, Jorge E Romaguera, Michelle A Fanale, Hun J Lee, Francesco Turturro, Felipe Samaniego, Sattva S Neelapu, M Alma Rodriguez, Nathan H Fowler, Michael Wang, Richard E Davis, Loretta J Nastoupil
BACKGROUND: The number of elderly patients with diffuse large B-cell lymphoma (DLBCL) in our aging society continues to rise, although the optimal management of very elderly patients with DLBCL is unknown. METHODS: This study evaluated 207 patients who were 80 years old or older at the diagnosis of DLBCL from 2002 to 2014 at The University of Texas MD Anderson Cancer Center. Analyzed features included clinical characteristics, treatment outcomes, and tolerability of therapy...
October 15, 2016: Cancer
https://www.readbyqxmd.com/read/27737845/cll-an-acquired-immunodeficiency-disease
#7
Clive S Zent
No abstract text is available yet for this article.
October 13, 2016: Blood
https://www.readbyqxmd.com/read/27664263/newly-diagnosed-and-relapsed-follicular-lymphoma-esmo-clinical-practice-guidelines-for-diagnosis-treatment-and-follow-up
#8
M Dreyling, M Ghielmini, S Rule, G Salles, U Vitolo, M Ladetto
No abstract text is available yet for this article.
September 2016: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/27799164/how-i-treat-cryoglobulinemia
#9
Eli Muchtar, Hila Magen, Morie A Gertz
Cryoglobulinemia is a distinct entity catheterized by the presence of cryoglobulins in the serum. Cryoglobulins differ in their composition, which has an impact on the clinical presentation and the underlying disease triggering cryoglobulin formation. Cryoglobulinemia is categorized into two main subgroups: Type I seen exclusively in clonal hematological diseases, and mixed cryoglobulinemia (type II/III) seen in HCV infection and systemic diseases such as B-cell lineage hematological malignancies and connective tissue disorders...
October 31, 2016: Blood
https://www.readbyqxmd.com/read/27187305/surveillance-imaging-in-patients-in-remission-from-hodgkin-and-diffuse-large-b-cell-lymphoma
#10
Chadi Nabhan, Sonali M Smith, Adam S Cifu
No abstract text is available yet for this article.
May 17, 2016: JAMA: the Journal of the American Medical Association
https://www.readbyqxmd.com/read/27049457/safety-tolerability-and-preliminary-activity-of-cudc-907-a-first-in-class-oral-dual-inhibitor-of-hdac-and-pi3k-in-patients-with-relapsed-or-refractory-lymphoma-or-multiple-myeloma-an-open-label-dose-escalation-phase-1-trial
#11
Anas Younes, Jesus G Berdeja, Manish R Patel, Ian Flinn, John F Gerecitano, Sattva S Neelapu, Kevin R Kelly, Amanda R Copeland, Amy Akins, Myles S Clancy, Lucy Gong, Jing Wang, Anna Ma, Jaye L Viner, Yasuhiro Oki
BACKGROUND: Treatment options for patients with relapsed or refractory lymphoma and multiple myeloma are limited. CUDC-907 is an oral, first-in-class, small molecule that is designed to inhibit both histone deacetylase (HDAC) and PI3K enzymes, which are members of common oncogenic pathways in haematological malignancies. We aimed to assess overall safety and preliminary activity in this dose-escalation study of CUDC-907 monotherapy in patients with relapsed or refractory lymphoma and multiple myeloma...
May 2016: Lancet Oncology
https://www.readbyqxmd.com/read/27643872/outcomes-of-diffuse-large-b-cell-lymphoma-patients-relapsing-after-autologous-stem-cell-transplantation-an-analysis-of-patients-included-in-the-coral-study
#12
E Van Den Neste, N Schmitz, N Mounier, D Gill, D Linch, M Trneny, R Bouadballah, J Radford, M Bargetzi, V Ribrag, U Dührsen, D Ma, J Briere, C Thieblemont, E Bachy, C H Moskowitz, B Glass, C Gisselbrecht
In the CORAL study, 255 chemosensitive relapses with diffuse large B-cell lymphoma (DLBCL) were consolidated with autologous stem cell transplantation (ASCT), and 75 of them relapsed thereafter. The median time between ASCT and progression was 7.1 months. The median age was 56.1 years; tertiary International Prognosis Index (tIPI) observed at relapse was 0-2 in 71.6% of the patients and >2 in 28.4%. The overall response rate to third-line chemotherapy was 44%. The median overall survival (OS) was 10.0 months (median follow-up: 32...
September 19, 2016: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/27151994/engage-501-phase-ii-study-of-entinostat-sndx-275-in-relapsed-and-refractory-hodgkin-lymphoma
#13
Connie Lee Batlevi, Yvette Kasamon, R Gregory Bociek, Peter Lee, Lia Gore, Amanda Copeland, Rachel Sorensen, Peter Ordentlich, Scott Cruickshank, Lori Kunkel, Daniela Buglio, Francisco Hernandez-Ilizaliturri, Anas Younes
Classical Hodgkin lymphoma treatment is evolving rapidly with high response rates from antibody-drug conjugates targeting CD30 and immune checkpoint antibodies. However, most patients do not achieve a complete response, therefore development of novel therapies is warranted to improve patient outcomes. In this phase II study, patients with relapsed or refractory Hodgkin lymphoma were treated with entinostat, an isoform selective histone deacetylase inhibitor. Forty-nine patients were enrolled: 33 patients on Schedule A (10 or 15 mg oral entinostat once every other week); 16 patients on Schedule B (15 mg oral entinostat once weekly in 3 of 4 weeks)...
August 2016: Haematologica
https://www.readbyqxmd.com/read/27247321/prolonged-disease-free-survival-in-elderly-relapsed-diffuse-large-b-cell-lymphoma-patients-treated-with-lenalidomide-plus-rituximab
#14
LETTER
Pier Luigi Zinzani, Cinzia Pellegrini, Lisa Argnani, Alessandro Broccoli
No abstract text is available yet for this article.
September 2016: Haematologica
https://www.readbyqxmd.com/read/27248633/new-agents-to-treat-chronic-lymphocytic-leukemia
#15
LETTER
Harriet S Walter, Gilles A Salles, Martin J S Dyer
No abstract text is available yet for this article.
June 2, 2016: New England Journal of Medicine
https://www.readbyqxmd.com/read/27207800/cd19-targeted-car-t-cell-therapeutics-for-hematologic-malignancies-interpreting-clinical-outcomes-to-date
#16
REVIEW
Jae H Park, Mark B Geyer, Renier J Brentjens
Adoptive transfer of T cells genetically modified to express chimeric antigen receptors (CARs) targeting CD19 has produced impressive results in treating patients with B-cell malignancies. Although these CAR-modified T cells target the same antigen, the designs of CARs vary as well as several key aspects of the clinical trials in which these CARs have been studied. It is unclear whether these differences have any impact on clinical outcome and treatment-related toxicities. Herein, we review clinical results reflecting the investigational use of CD19-targeted CAR T-cell therapeutics in patients with B-cell hematologic malignancies, in light of differences in CAR design and production, and outline the limitations inherent in comparing outcomes between studies...
June 30, 2016: Blood
https://www.readbyqxmd.com/read/27207799/toxicities-of-chimeric-antigen-receptor-t-cells-recognition-and-management
#17
REVIEW
Jennifer N Brudno, James N Kochenderfer
Chimeric antigen receptor (CAR) T cells can produce durable remissions in hematologic malignancies that are not responsive to standard therapies. Yet the use of CAR T cells is limited by potentially severe toxicities. Early case reports of unexpected organ damage and deaths following CAR T-cell therapy first highlighted the possible dangers of this new treatment. CAR T cells can potentially damage normal tissues by specifically targeting a tumor-associated antigen that is also expressed on those tissues. Cytokine release syndrome (CRS), a systemic inflammatory response caused by cytokines released by infused CAR T cells can lead to widespread reversible organ dysfunction...
June 30, 2016: Blood
https://www.readbyqxmd.com/read/27178240/venetoclax-in-relapsed-or-refractory-chronic-lymphocytic-leukaemia-with-17p-deletion-a-multicentre-open-label-phase-2-study
#18
Stephan Stilgenbauer, Barbara Eichhorst, Johannes Schetelig, Steven Coutre, John F Seymour, Talha Munir, Soham D Puvvada, Clemens-Martin Wendtner, Andrew W Roberts, Wojciech Jurczak, Stephen P Mulligan, Sebastian Böttcher, Mehrdad Mobasher, Ming Zhu, Monali Desai, Brenda Chyla, Maria Verdugo, Sari Heitner Enschede, Elisa Cerri, Rod Humerickhouse, Gary Gordon, Michael Hallek, William G Wierda
BACKGROUND: Deletion of chromosome 17p (del[17p]) in patients with chronic lymphocytic leukaemia confers very poor prognosis when treated with standard chemo-immunotherapy. Venetoclax is an oral small-molecule BCL2 inhibitor that induces chronic lymphocytic leukaemia cell apoptosis. In a previous first-in-human study of venetoclax, 77% of patients with relapsed or refractory chronic lymphocytic leukaemia achieved an overall response. Here we aimed to assess the activity and safety of venetoclax monotherapy in patients with relapsed or refractory del(17p) chronic lymphocytic leukaemia...
June 2016: Lancet Oncology
https://www.readbyqxmd.com/read/27184627/financial-hardship-and-patient-reported-outcomes-after-hematopoietic-cell-transplantation
#19
Gregory A Abel, Randy Albelda, Nandita Khera, Theresa Hahn, Diana Y Salas Coronado, Oreofe O Odejide, Kira Bona, Reginald Tucker-Seeley, Robert Soiffer
Although hematopoietic cell transplantation (HCT) is the only curative therapy for many advanced hematologic cancers, little is known about the financial hardship experienced by HCT patients nor the association of hardship with patient-reported outcomes. We mailed a 43-item survey to adult patients approximately 180 days after their first autologous or allogeneic HCT at 3 high-volume centers. We assessed decreases in household income; difficulty with HCT-related costs, such as need to relocate or travel; and 2 types of hardship: hardship_1 (reporting 1 or 2 of the following: dissatisfaction with present finances, difficulty meeting monthly bill payments, or not having enough money at the end of the month) and "hardship_2" (reporting all 3)...
August 2016: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/27090170/fdg-pet-imaging-in-hematological-malignancies
#20
REVIEW
L Valls, C Badve, S Avril, K Herrmann, P Faulhaber, J O'Donnell, N Avril
The majority of aggressive lymphomas is characterized by an up regulated glycolytic activity, which enables the visualization by F-18 FDG-PET/CT. One-stop hybrid FDG-PET/CT combines the functional and morphologic information, outperforming both, CT and FDG-PET as separate imaging modalities. This has resulted in several recommendations using FDG-PET/CT for staging, restaging, monitoring during therapy, and assessment of treatment response as well as identification of malignant transformation. FDG-PET/CT may obviate the need for a bone marrow biopsy in patients with Hodgkin's lymphoma and diffuse large B cell lymphoma...
July 2016: Blood Reviews
label_collection
label_collection
6645
1
2
2016-05-23 11:23:27
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"